Shuji Ozaki

5.1k total citations
134 papers, 3.6k citations indexed

About

Shuji Ozaki is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Shuji Ozaki has authored 134 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Hematology, 63 papers in Molecular Biology and 47 papers in Oncology. Recurrent topics in Shuji Ozaki's work include Multiple Myeloma Research and Treatments (61 papers), Peptidase Inhibition and Analysis (24 papers) and Monoclonal and Polyclonal Antibodies Research (19 papers). Shuji Ozaki is often cited by papers focused on Multiple Myeloma Research and Treatments (61 papers), Peptidase Inhibition and Analysis (24 papers) and Monoclonal and Polyclonal Antibodies Research (19 papers). Shuji Ozaki collaborates with scholars based in Japan, United States and Greece. Shuji Ozaki's co-authors include Toshio Matsumoto, Masahiro Abe, Hirokazu Miki, Toshihiro Hashimoto, Shinsuke Kido, Michihiro Nakamura, Kazunori Ishimura, Masaaki Kosaka, Koichiro Hayashi and Hironobu Shibata and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Shuji Ozaki

124 papers receiving 3.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shuji Ozaki Japan 30 1.4k 1.4k 1.3k 681 542 134 3.6k
Nadia Carlesso United States 32 973 0.7× 2.7k 2.0× 1.3k 1.0× 1.1k 1.6× 538 1.0× 65 5.5k
Joel A. Spencer United States 23 1.9k 1.3× 1.9k 1.4× 741 0.6× 720 1.1× 1.1k 2.0× 42 5.4k
J.B.M. Boezeman Netherlands 31 456 0.3× 971 0.7× 1.0k 0.8× 1.1k 1.6× 317 0.6× 94 3.8k
Natarajan Muthusamy United States 40 1.3k 0.9× 2.3k 1.6× 649 0.5× 2.0k 2.9× 317 0.6× 177 5.3k
Ralf Huss Germany 35 971 0.7× 1.1k 0.8× 382 0.3× 696 1.0× 282 0.5× 111 3.9k
Charles K. F. Chan United States 26 1.1k 0.8× 1.5k 1.1× 313 0.2× 1.4k 2.0× 617 1.1× 59 4.2k
Robert A.J. Oostendorp Germany 35 664 0.5× 1.6k 1.2× 1.2k 0.9× 1.1k 1.6× 265 0.5× 109 3.8k
Ute Reuning Germany 34 1.2k 0.8× 1.8k 1.3× 639 0.5× 586 0.9× 446 0.8× 83 4.3k
Lesley G. Ellies United States 47 1.5k 1.1× 3.6k 2.6× 354 0.3× 2.0k 2.9× 940 1.7× 82 6.9k
Katherine N. Weilbaecher United States 46 3.2k 2.3× 2.5k 1.8× 592 0.4× 1.3k 1.9× 349 0.6× 124 6.1k

Countries citing papers authored by Shuji Ozaki

Since Specialization
Citations

This map shows the geographic impact of Shuji Ozaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shuji Ozaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shuji Ozaki more than expected).

Fields of papers citing papers by Shuji Ozaki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shuji Ozaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shuji Ozaki. The network helps show where Shuji Ozaki may publish in the future.

Co-authorship network of co-authors of Shuji Ozaki

This figure shows the co-authorship network connecting the top 25 collaborators of Shuji Ozaki. A scholar is included among the top collaborators of Shuji Ozaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shuji Ozaki. Shuji Ozaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Konishi, Tatsuya, Jun Yamanouchi, Takao NISHIDA, et al.. (2025). HIV-associated neurocognitive dysfunction in the Chugoku-Shikoku region of Japan: A cross-sectional study. Journal of Infection and Chemotherapy. 31(8). 102768–102768.
2.
Inoue, Yusuke, Jumpei Teramachi, Asuka Oda, et al.. (2024). Elotuzumab‐mediated ADCC with Th1‐like Vγ9Vδ2 T cells to disrupt myeloma–osteoclast interaction. Cancer Science. 116(2). 559–563. 1 indexed citations
3.
Handa, Hiroshi, et al.. (2023). Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database. PLoS ONE. 18(4). e0283931–e0283931. 7 indexed citations
4.
5.
Harada, Takeshi, Hiroto Ohguchi, Asuka Oda, et al.. (2022). Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase. Blood Advances. 7(6). 1019–1032. 2 indexed citations
6.
Ozaki, Shuji, Hiroshi Handa, Hiromi Koiso, et al.. (2021). Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Journal of Cancer Research and Clinical Oncology. 148(1). 191–203. 2 indexed citations
7.
Iida, Shinsuke, Takashi Watanabe, Morio Matsumoto, et al.. (2019). Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study. Cancer Science. 110(9). 2924–2932. 6 indexed citations
8.
Kodama, Toshio, Tomoaki Fujisaki, Yoshitaka Imaizumi, et al.. (2019). Treatment-associated outcomes of patients with primary ocular adnexal MALT lymphoma after accurate diagnosis. International Journal of Clinical Oncology. 24(12). 1620–1628. 7 indexed citations
9.
Ozaki, Shuji, Hiroshi Handa, Takayuki Saitoh, et al.. (2019). Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma. Annals of Hematology. 98(7). 1703–1711. 9 indexed citations
10.
Miki, Hirokazu, Takeshi Harada, Qu Cui, et al.. (2016). Expansion of γδT Cells By New Generation IMiDs and Their Cytotoxicity Against Myeloma Progenitors. Blood. 128(22). 2107–2107. 1 indexed citations
11.
Ozaki, Shuji, et al.. (2016). [Multiple Myeloma: from Diagnosis to the Up-to-date Treatment. Topics: III. Bone Disease in Multiple Myeloma].. PubMed. 105(7). 1216–23. 1 indexed citations
12.
Harada, Takeshi, Shuji Ozaki, Asuka Oda, et al.. (2013). Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma. International Journal of Hematology. 97(6). 743–748. 20 indexed citations
13.
Harada, Takeshi, Shuji Ozaki, Asuka Oda, et al.. (2013). Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors. PLoS ONE. 8(12). e83905–e83905. 13 indexed citations
14.
Ozaki, Shuji, et al.. (2012). QUANTITATIVE FLOW CYTOMETRIC ANALYSIS OF A AND B ANTIGENS IN 15 PATIENTS WITH cisA2B3 BLOOD GROUP. Japanese Journal of Transfusion and Cell Therapy. 58(3). 448–455.
15.
Nakano, Ayako, Masahiro Abe, Daisuke Tsuji, et al.. (2011). Inhibition of Hexokinase II Inactivates ABC Transporters and Restores Drug Sensitivity in Myeloma Cells. Blood. 118(21). 135–135. 1 indexed citations
16.
Takeuchi, Kyoko, Masahiro Abe, Masahiro Hiasa, et al.. (2010). TGF-β Inhibition Restores Terminal Osteoblast Differentiation to Suppress Myeloma Growth. PLoS ONE. 5(3). e9870–e9870. 108 indexed citations
17.
Wang, Wei, Yasuhiko Nishioka, Shuji Ozaki, et al.. (2008). HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody. Cancer Immunology Immunotherapy. 58(6). 967–976. 54 indexed citations
18.
Ozaki, Shuji, Osamu Tanaka, Shiro Fujii, et al.. (2007). Therapy with Bortezomib plus Dexamethasone Induces Osteoblast Activation in Responsive Patients with Multiple Myeloma. International Journal of Hematology. 86(2). 180–185. 42 indexed citations
19.
Ozaki, Shuji, et al.. (1994). Characterization of a novel interleukin-6 autocrine-dependent human plasma cell line.. PubMed. 8(12). 2207–13. 10 indexed citations
20.
Kawachi, Yasunori, Shuji Ozaki, Tatsumi Uchida, et al.. (1994). Richter's Syndrome Showing Pronounced Lymphadenopathy in Response to Administration of Granulocyte Colony-Stimulating Factor. Leukemia & lymphoma. 13(5-6). 509–514. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nadia Carlesso Breakdown of academic impact, for papers by Joel A. Spencer Breakdown of academic impact, for papers by J.B.M. Boezeman Breakdown of academic impact, for papers by Natarajan Muthusamy Breakdown of academic impact, for papers by Ralf Huss Breakdown of academic impact, for papers by Charles K. F. Chan Breakdown of academic impact, for papers by Robert A.J. Oostendorp Breakdown of academic impact, for papers by Ute Reuning Breakdown of academic impact, for papers by Lesley G. Ellies Breakdown of academic impact, for papers by Katherine N. Weilbaecher
Rankless by CCL
2026